Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

MeSH Review:

Biopharmaceutics

Verbeeck, R.K., Tannergren, C., Vogelpoel, H., Rege, B.D., Varma, M.V., et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text.

Ideally this entry shall become one comprehensive and continuous article. Bulleted lists, for instance, were only used because it is impossible to automatically integrate independent facts into a continuous text.

Much of the current information on this page has been automatically compiled from Pubmed.

This precompiled information serves as a substrate and matrix to embed your contributions, but it is by no means the final word - Homo sapiens can do much better!

WikiGenes is a non-profit and open access community project.

High impact information on Biopharmaceutics

Feasibility of Biowaiver Extension to Biopharmaceutics Classification System Class III Drug Products : Cimetidine [1].
Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations [2].
Biopharmaceutics of a new transdermal fentanyl device [3].
According to the current Biopharmaceutics Classification System (BCS), cimetidine would be assigned to Class III [4].
Literature data are reviewed on the properties of acetaminophen (paracetamol) related to the biopharmaceutics classification system (BCS) [5].

Biological context of Biopharmaceutics

The Biopharmaceutics Classification System (BCS) allows waivers of in vivo bioequivalence for rapidly dissolving immediate-release (IR) formulations of drugs with high solubility and high permeability [6].
Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms [7].

Anatomical context of Biopharmaceutics

AIMS: To investigate whether the drug-drug interaction between fexofenadine and ketoconazole is localized to efflux transport proteins of the small intestine, and to determine and classify the effective jejunal permeability (Peff) of fexofenadine according to the Biopharmaceutics Classification System (BCS) [8].
A set of standard compounds (marketed compounds) belonging to the various class of Biopharmaceutics Classification System (BCS) were used to assess the utility of the 96 well Caco-2 cells [9].

Associations of Biopharmaceutics with chemical compounds

According to the current Biopharmaceutics Classification System (BCS), ranitidine hydrochloride should be assigned to Class III [10].
Literature data are reviewed on the properties of ibuprofen related to the biopharmaceutics classification system (BCS) [11].
Literature data on the properties of chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride related to the Biopharmaceutics Classification System (BCS) are reviewed [12].
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol [13].
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride [12].

Gene context of Biopharmaceutics

Biopharmaceutics of liposomal interleukin 2, oncolipin [14].
Thus, integrating these factors with drug characteristics of the Biopharmaceutics Classification System (BCS) class better predicts the functional role of P-gp in limiting intestinal drug absorption [15].

References

Feasibility of Biowaiver Extension to Biopharmaceutics Classification System Class III Drug Products : Cimetidine. Jantratid, E., Prakongpan, S., Amidon, G.L., Dressman, J.B. Clinical pharmacokinetics. (2006)
Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part II. Physiological considerations. Martinez, M., Amidon, G., Clarke, L., Jones, W.W., Mitra, A., Riviere, J. Adv. Drug Deliv. Rev. (2002)
Biopharmaceutics of a new transdermal fentanyl device. Fiset, P., Cohane, C., Browne, S., Brand, S.C., Shafer, S.L. Anesthesiology (1995)
Biowaiver monographs for immediate release solid oral dosage forms: Cimetidine. Jantratid, E., Prakongpan, S., Dressman, J.B., Amidon, G.L., Junginger, H.E., Midha, K.K., Barends, D.M. Journal of pharmaceutical sciences. (2006)
Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). Kalantzi, L., Reppas, C., Dressman, J.B., Amidon, G.L., Junginger, H.E., Midha, K.K., Shah, V.P., Stavchansky, S.A., Barends, D.M. Journal of pharmaceutical sciences. (2006)
Effect of common excipients on Caco-2 transport of low-permeability drugs. Rege, B.D., Yu, L.X., Hussain, A.S., Polli, J.E. Journal of pharmaceutical sciences. (2001)
Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms. Garrett, E.R., Roseboom, H., Green, J.R., Schuermann, W. International journal of clinical pharmacology and biopharmacy. (1978)
The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Tannergren, C., Knutson, T., Knutson, L., Lennernäs, H. British journal of clinical pharmacology. (2003)
Validation of the 96 well Caco-2 cell culture model for high throughput permeability assessment of discovery compounds. Marino, A.M., Yarde, M., Patel, H., Chong, S., Balimane, P.V. International journal of pharmaceutics. (2005)
Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. Kortejärvi, H., Yliperttula, M., Dressman, J.B., Junginger, H.E., Midha, K.K., Shah, V.P., Barends, D.M. Journal of pharmaceutical sciences. (2005)
Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. Potthast, H., Dressman, J.B., Junginger, H.E., Midha, K.K., Oeser, H., Shah, V.P., Vogelpoel, H., Barends, D.M. Journal of pharmaceutical sciences. (2005)
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride. Verbeeck, R.K., Junginger, H.E., Midha, K.K., Shah, V.P., Barends, D.M. Journal of pharmaceutical sciences. (2005)
Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. Vogelpoel, H., Welink, J., Amidon, G.L., Junginger, H.E., Midha, K.K., Möller, H., Olling, M., Shah, V.P., Barends, D.M. Journal of pharmaceutical sciences. (2004)
Biopharmaceutics of liposomal interleukin 2, oncolipin. Neville, M.E., Boni, L.T., Pflug, L.E., Popescu, M.C., Robb, R.J. Cytokine (2000)
Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Varma, M.V., Sateesh, K., Panchagnula, R. Mol. Pharm. (2005)